


BIOPHARMACEUTICALS



HALO 160 Å PCS C18 vs. C18 Peptide Panel





TEST CONDITIONS:

Column: HALO 160 Å PCS C18, 2.7 µm, 2.1 x 100 mm

Part Number: 92812-617

Comparison Column: SPP 160 Å C18, 2.7 µm, 2.1 x 100 mm

Mobile Phase A: Water/ 0.1% Formic Acid Mobile Phase B: Acetonitrile/ 0.1% Formic Acid

Gradient: Time %B 0.0 2 10.0 35

Flow Rate: 0.3 mL/min Temperature: 30 °C Injection Volume: 1.0 µL Wavelength: PDA, 280 nm

Flow Cell: 1 µL Data Rate: 100 Hz Response Time: 0.025 sec. LC System: Shimadzu Nexera X2

PEAK IDENTITIES

1. Uracil

S1Y Sequence: RGAGGLYLGK-NH2
S2Y Sequence: Ac-RGGGGLYLGK-NH2
S3Y Sequence: Ac-RGAGGLYLGK-NH2
S4Y2 Sequence: Ac-RGVGYLGLGK-NH2
S5Y Sequence: Ac-RGVVGLYLGK-NH2

7. Insulin Chain B Oxidized

A synthetic peptide panel is screened on 160 Å PCS C18 compared to a C18 stationary phase. While using low ionic strength mobile phases such as formic acid the positively charged surface stationary phase shows narrower peak widths and improved peak asymmetry when compared to a traditional C18 stationary phase without endcapping.



